1887

Abstract

Daptomycin is a novel bactericidal agent active against Gram-positive pathogens including meticillin-resistant (MRSA). Our case is unique in the description of an MRSA USA 300 isolate that developed decreased susceptibility to daptomycin during daptomycin and vancomycin therapy. Directed sequencing detected a previously reported mutation in , resulting in a T345A substitution, associated with non-susceptibility to daptomycin.

Loading

Article metrics loading...

/content/journal/jmm/10.1099/jmm.0.2008/000588-0
2008-08-01
2019-11-12
Loading full text...

Full text loading...

/deliver/fulltext/jmm/57/8/1036.html?itemId=/content/journal/jmm/10.1099/jmm.0.2008/000588-0&mimeType=html&fmt=ahah

References

  1. Alborn, W. E., Allen, N. E. & Preston, D. A. ( 1991; ). Daptomycin disrupts membrane potential in growing Staphylococcus aureus. Antimicrob Agents Chemother 35, 2282–2287.[CrossRef]
    [Google Scholar]
  2. Bannerman, T. L., Hancock, G. A., Tenover, F. C. & Miller, J. M. ( 1995; ). Pulsed-field gel electrophoresis as a replacement for bacteriophage typing of Staphylococcus aureus. J Clin Microbiol 33, 551–555.
    [Google Scholar]
  3. CLSI ( 2007; ). Performance Standards for Antimicrobial Susceptibility Testing. Approved Standards M100-S17. Wayne, PA: Clinical and Laboratory Standards Institute.
  4. Cui, L., Tominaga, E., Neoh, H. & Hiramatsu, K. ( 2006; ). Correlation between reduced daptomycin susceptibility and vancomycin resistance in vancomycin intermediate Staphylococcus aureus. Antimicrob Agents Chemother 50, 1079–1082.[CrossRef]
    [Google Scholar]
  5. Diep, B. A., Gill, S. R., Chang, R. F., Phan, T. H., Chen, J. H., Davidson, M. G., Lin, F., Lin, J., Carleton, H. A. & other authors ( 2006; ). Complete genome sequence of USA300, an epidemic clone of community-acquired methicillin-resistant Staphylococcus aureus. Lancet 367, 731–739.[CrossRef]
    [Google Scholar]
  6. Eisenstein, B. I. ( 2004; ). Lipopeptides, focusing on daptomycin for the treatment of gram-positive infections. Expert Opin Investig Drugs 13, 1159–1169.[CrossRef]
    [Google Scholar]
  7. Fey, P. D., Said-Salim, B., Rupp, M. E., Hinrichs, S. H., Boxrud, D. J., Davis, C. C., Kreiswirth, B. N. & Schlievert, P. M. ( 2003; ). Comparative molecular analysis of community or hospital-acquired methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother 47, 196–203.[CrossRef]
    [Google Scholar]
  8. Friedman, L., Alder, J. D. & Silverman, J. A. ( 2006; ). Genetic changes that correlate with reduced susceptibility to daptomycin in Staphylococcus aureus. Antimicrob Agents Chemother 50, 2137–2145.[CrossRef]
    [Google Scholar]
  9. Jones, T., Yeaman, M. R., Sakoulas, G., Yang, S. J., Proctor, R. A., Sahl, H. G., Schrenzel, J., Xiong, Y. Q. & Bayer, A. S. ( 2008; ). Failures in clinical treatment of Staphylococcus aureus with daptomycin are associated with alterations in surface charge, membrane phospholipid asymmetry, and drug binding. Antimicrob Agents Chemother 52, 269–278.[CrossRef]
    [Google Scholar]
  10. Kaatz, G. W., Lundstrom, T. S. & Seo, S. M. ( 2006; ). Mechanisms of daptomycin resistance in Staphylococcus aureus. Int J Antimicrob Agents 28, 280–287.[CrossRef]
    [Google Scholar]
  11. Mangili, A., Bica, I., Snydman, R. & Hamer, D. H. ( 2005; ). Daptomycin-resistant methicillin-resistant Staphylococcus aureus bacteremia. Clin Infect Dis 40, 1058–1060.[CrossRef]
    [Google Scholar]
  12. Marty, F. M., Yeh, W. W., Wennersten, C. B., Venkataraman, L., Albano, E., Alyea, E. P., Gold, H. S., Baden, L. R. & Pillai, S. K. ( 2006; ). Emergence of a clinical daptomycin-resistant Staphylococcus aureus isolate during treatment of methicillin-resistant Staphylococcus aureus bacteremia and osteomyelitis. J Clin Microbiol 44, 595–597.[CrossRef]
    [Google Scholar]
  13. McDougal, L. K., Steward, C. D., Killgore, G. E., Chaitram, J. M., McAllister, S. K. & Tenover, F. C. ( 2003; ). Pulsed-field gel electrophoresis typing of oxacillin-resistant Staphylococcus aureus isolates from the United States: establishing a national database. J Clin Microbiol 41, 5113–5120.[CrossRef]
    [Google Scholar]
  14. Naimi, T. S., LeDell, K. H., Como-Sabetti, K., Borchardt, S. M., Boxrud, D. J., Etienne, J., Johnson, S. K., Vandenesch, F., Fridkin, S. & other authors ( 2003; ). Comparison of community- and health care-associated methicillin-resistant Staphylococcus aureus infection. JAMA 290, 2976–2984.[CrossRef]
    [Google Scholar]
  15. Sakoulas, G., Alder, J., Thauvin, C., Moellering, R. C. & Eliopolous, G. M. ( 2006; ). Induction of daptomycin heterogenous susceptibility in Staphylococcus aureus by exposure to vancomycin. Antimicrob Agents Chemother 50, 1581–1585.[CrossRef]
    [Google Scholar]
  16. Silverman, J. A., Perlmutter, N. G. & Shapiro, H. M. ( 2003; ). Correlation of daptomycin bactericidal activity and membrane depolarization in Staphylococcus aureus. Antimicrob Agents Chemother 47, 2538–2544.[CrossRef]
    [Google Scholar]
  17. Skiest, D. J. ( 2006; ). Treatment failure resulting from resistance of Staphylococcus aureus to daptomycin. J Clin Microbiol 44, 655–656.[CrossRef]
    [Google Scholar]
http://instance.metastore.ingenta.com/content/journal/jmm/10.1099/jmm.0.2008/000588-0
Loading
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error